A software-implemented business method could be patentable if programmed into a computer with “some ingenuity”, IP Australia told the Full Federal Court as a landmark appeal between rival tech companies Encompass and Infotrack wrapped up Friday.
AFT Pharmaceuticals has been ordered to pull advertisements for its painkiller Maxigesic after the Federal Court ruled in favour of rival Reckitt Benckiser, finding the ads breached Australian Consumer Law.
Fintech company Encompass has asked the Full Federal Court to take a more “nuanced” approach to software patentability than the one currently held by IP Australia, on the first day of a high-stakes appeal over the patentability of computer-related inventions.
Lawyers leading a class action against Quintis want the failed sandalwood oil producer to hand over evidence of any insurance policy that could cover the company and its founder for damages sought in the case.
A barrister for the ABC and Fairfax has told the Federal Court that an appeal against the dismissal of their truth defence in the Chau Chak Wing defamation case will have “massive ramifications for mass media”.
Bank of Queensland has lost a dispute with two insurers over coverage for a $6 million settlement of a class action brought by investors in a Ponzi scheme by jailed scammer Bradley Sherwin, with a judge shooting down the bank’s argument that the class action should only be considered one claim under the policy.
The judge overseeing Geoffrey Rush’s defamation trial interjected in Nationwide News’ closing submissions on Wednesday, expressing doubt about the publisher’s interpretation of evidence — including a text message with a tongue emoji Rush sent to his accuser — said to back its defence in the case.
A defamation case brought by Greens senator Sarah Hanson-Young against fellow senator David Leyonhjelm will go ahead after Leyonhjelm lost a bid to shut the suit down on the grounds of parliamentary privilege.
The former chief executive officer of Sydney’s Parramatta Council is suing Fairfax Media, saying three articles published in the Sydney Morning Herald accusing him of lying on his resume were defamatory.
The Commonwealth of Australia is weighing a bid to strike out Otsuka Pharmaceutical’s defence as the government seeks lost subsidies after an almost seven-year long patent dispute over the antipsychotic drug, Abilify.